← Return to Question whether to add Abiraterone to treatment or not?

Discussion

Question whether to add Abiraterone to treatment or not?

Prostate Cancer | Last Active: May 29 11:15am | Replies (19)
Comment receiving replies
@northoftheborder

Out of interest, I thought it would be useful to collect the approvals for the different common ARSIs. Mini-glossary at the end. Please verify everything you read here, since it's based just on some quick web searches.

1st gen ARSI:

Abiraterone (Zytiga): mCRPC; mCSPC only for high-risk; both also require the steroid Prednisone

2nd gen ARSI:

Enzalutamide (Xtandi): nmCRPC, mCRPC, mCSPC; sometimes nmCSPC if there's a high risk of recurrence
Apalutamide (Erleada): nmCRPC, mCSPC
Darolutamide (Nubeqa): nmCRPC; mCSPC (with Doxecetol, a chemo drug)

Mini-glossary:

nmCSPC - non-metastatic, castrate-sensitive prostate cancer
mCSPC - metastatic, castrate-sensitive prostate cancer
nmCRPC - non-metastatic, castrate-resistant prostate cancer
mCRPC - metastatic, castrate-resistant prostate cancer

Jump to this post

Replies to "Out of interest, I thought it would be useful to collect the approvals for the different..."
jeff Marchi | @jeffmarc | May 14 3:00pm

While all these guidelines you have listed here Apply in most cases there are quite a few exceptions.

Many people that I know through Ancan.org are on Darolutamide and are mCRPC, including me. Many doctors are prescribing it. No chemo either.

VIEW AND REPLY